LBA43 Updated response data and analysis of progression free survival by mechanism of mismatch repair loss in endometrial cancer (EC) patients (pts) treated with pembrolizumab plus carboplatin/paclitaxel (CP) as compared to CP plus placebo (PBO) in the NRG GY018 trial

Ramez N. Eskander, Michael W. Sill, Austin Miller, Lucas R. Beffa, Richard G. Moore, Joanie Mayer Hope, Fernanda Musa, Robert S. Mannel, Mark S. Shahin, G. Canturia, Eugenia Girda, Cara Mathews, Juraj Kavecansky, Charles A. Leath, Lilian T. Gien, Erin Hinchcliff, Shashikant Lele, Matthew A. Powell, Carol Aghajanian